News|Articles|March 18, 2022
NeurologyLive® Friday 5 — March 18, 2022
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 18, 2022.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Muscular Dystrophy Association Clinical and Scientific Conference
The annual Muscular Dystrophy Association's Clinical & Scientific Conference took place this week, March 13-16. The NeurologyLive® team was on-site and is providing coverage, including in-depth conversations with experts and opinion leaders, as well as the latest on data readouts and sessions.
2: NeuroVoices: Sharon Cohen, MD, FRCPC, on the Diagnostic Potential of Retinal Imaging for Alzheimer Disease
The neurologist and assistant professor at the University of Toronto discussed the advantages hyperspectral retinal imaging tools like RetiSpec offer to clinical care, and when clinicians can expect to see them become commonplace in the diagnosis of AD.
3: Long-Term Data on Aducanumab Demonstrates Persistent Amyloid Depletion
Newly announced long-term findings from the pivotal phase 3 EMERGE and ENGAGE studies and phase 1b PRIME study showed that treatment with the 100 mg/mL injection significantly reduced amyloid-β plaque levels over 2 years of follow-up.
4: Peers & Perspectives: Parkinson and COMT Inhibitors
In Episode 7 of this NeurologyLive® Peers & Perspectives series, "Parkinson Disease: Managing Off-Episodes," Cynthia Comella, MD, discusses the importance of having COMT inhibitors as a therapeutic option for patients with Parkinson’s disease that are having off-episodes.
5: Insights: Disease-Modifying Therapies and the Immune System
In Episode 2 of this NeurologyLive® Insights series, "Management of Multiple Sclerosis in the Era of COVID-19 Pandemic," Klaus Schmierer, MBBS, PhD, FRCP, introduces the disease-modifying therapies (DMT) that are available for patients with MS and their impact on the immune system.
—————————————————
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
5